Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery
- PMID: 850438
Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery
Abstract
Two protocols of heparin management during cardiopulmonary bypass were compared to assess the role of the activated clotting time (ACT) in relation to postoperative blood loss. The study was divided into two groups: Group I, the control group, in which 3 mg. of heparin per kilogram was given as the initial dose and maintained at a dose of 1.5 mg. per kilogram every 45 minutes during cardiopulmonary bypass, and Group II, in which the initail dose of heparin was 2 mg. per kilogram and additional dosage were based upon the ACT. We found a striking decrease in postoperative blood loss as well as a decrease in the amount of heparin administered during cardiopulmonary during cardiopulmonary bypass in Group II patients. In addition, less protamine was required to neutralize the heparin in the second group after bypass. Thus, when patients are given too much heparin, as in our control group, the effectiveness of protamine is decreased. We would like to stress the value of the ACT in controlling heparin administration as well as postoperative blood loss in cardiopulmonary bypass surgery.
Similar articles
-
Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.J Thorac Cardiovasc Surg. 1990 Mar;99(3):518-27. J Thorac Cardiovasc Surg. 1990. PMID: 2308370
-
[Haemochron--a simple method of monitoring heparin level during extracorporeal circulation].Chir Forum Exp Klin Forsch. 1978;(1978):119-22. Chir Forum Exp Klin Forsch. 1978. PMID: 752575 German.
-
Monitoring of blood coagulation in open heart surgery. II. Use of individualized dosages of heparin and protamine controlled by activated coagulation times.Acta Anaesthesiol Belg. 1980;31(2):121-8. Acta Anaesthesiol Belg. 1980. PMID: 7468138
-
Safety issues in heparin and protamine administration for extracorporeal circulation.J Cardiothorac Vasc Anesth. 1998 Apr;12(2 Suppl 1):17-20. J Cardiothorac Vasc Anesth. 1998. PMID: 9583571 Review.
-
Blood coagulation and autologous blood transfusion in cardiac surgery.J Clin Anesth. 1990 Nov-Dec;2(6):393-406. doi: 10.1016/0952-8180(90)90026-y. J Clin Anesth. 1990. PMID: 2271204 Review.
Cited by
-
The efficacy and safety of a pharmacologic protocol for maintaining coronary artery bypass patients at a higher mean arterial pressure during cardiopulmonary bypass. 1998.J Extra Corpor Technol. 2013 Sep;45(3):198-206. J Extra Corpor Technol. 2013. PMID: 24303604 Free PMC article. Clinical Trial.
-
Excessive requirement for heparin during cardiac surgery.Can Anaesth Soc J. 1981 May;28(3):280-2. doi: 10.1007/BF03005516. Can Anaesth Soc J. 1981. PMID: 7237224
-
The hemostatic defect of cardiopulmonary bypass.J Thromb Thrombolysis. 2003 Dec;16(3):129-47. doi: 10.1023/B:THRO.0000024051.12177.e9. J Thromb Thrombolysis. 2003. PMID: 15087599 Review.
-
Clinical monitoring of activated clotting time during cardiothoracic surgery: comparing the Hemochron® Response and Hemochron® Signature Elite.Perfusion. 2023 Mar;38(2):285-291. doi: 10.1177/02676591211049316. Epub 2021 Oct 1. Perfusion. 2023. PMID: 34596463 Free PMC article.
-
Blood transfusion requirements in coronary artery surgery with and without the activated clotting time (ACT) technique.Klin Wochenschr. 1985 Mar 15;63(6):252-6. doi: 10.1007/BF01731470. Klin Wochenschr. 1985. PMID: 3872962
MeSH terms
Substances
LinkOut - more resources
Medical